Classical Hodgkin Lymphoma: From Past to Future—A Comprehensive Review of Pathophysiology and Therapeutic Advances
Faryal Munir(The University of Texas MD Anderson Cancer Center), Sajad Khazal(The University of Texas MD Anderson Cancer Center), Viney Hardit(The University of Texas MD Anderson Cancer Center), Irtiza Sheikh(The University of Texas MD Anderson Cancer Center), Branko Cuglievan(The University of Texas MD Anderson Cancer Center), Jiasen He(The University of Texas MD Anderson Cancer Center), Shaikha AlQahtani(The University of Texas MD Anderson Cancer Center), Chitra Hosing(The University of Texas MD Anderson Cancer Center), Priti Tewari(The University of Texas MD Anderson Cancer Center)
Cited by 54
Related Papers
Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma
|New England Journal of Medicine|2018|584
Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial
|Nature Medicine|2024|452
Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial
|Journal of Clinical Oncology|2013|439
Optimizing Autologous Stem Cell Mobilization Strategies to Improve Patient Outcomes: Consensus Guidelines and Recommendations
|Biology of Blood and Marrow Transplantation|2013|402
Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy
|Nature Reviews Clinical Oncology|2018|237